Literature DB >> 33331305

[Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].

Y Z Gan1, Y H Li1, L H Zhang2, L Ma3, W W He4, Y B Jin1, Y An1, Z G Li1, H Ye1.   

Abstract

OBJECTIVE: To study the differences between clinically amyopathic dermatomyositis (CADM) and typical dermatomyositis (DM) on clinical and immunological features.
METHODS: By collecting clinical data of 106 CADM patients and 158 DM patients from January 2010 to June 2019 in the department of Rheumatology and Immunology, Peking University People's Hospital, the clinical characteristics and immunological features in the two groups were compared, and the distribution characters and the clinical meanings of myositis autoantibodies were discussed in the two groups respectively. Myositis autoantibodies were measured by immunoblotting according to the manufacturers' instructions.
RESULTS: In the aspects of clinical manifestations, CADM presented more with onset of interstial lung diseases (ILD) compared with DM (20.7% vs. 7.6%, P=0.002), and CADM-ILD was more likely to be acute ILD (58.3% vs. 26%, P < 0.001), and there were no differences between CADM and DM in cutaneous manifestations, accompanied with connective tissue disease (CTD) and malignancy. In CADM, the positive rate of rheumatoid factors and antinuclear antibodies was lower in DM. The most common myositis specific autoantibodies (MSAs) in CADM were anti-MDA5 (36%), anti-PL-7 (11.2%) and anti-TIF-1γ (10.1%). The most common MSAs in DM were anti-Jo-1 (19.2%), anti-TIF-1γ (11.5%) and anti-MDA5 (11.5%). Anti-MDA5 was correlated with acute ILD and skin ulceration both in CADM and DM; in CADM, skin ulceration was not associated with the titer of anti-MDA5; while in DM, skin ulceration was associated with high titer of anti-MDA5. In DM, anti-TIF-1γ was correlated with heliotrope eruption, V/shawl neck sign, perionychia erythma and malignancy, and higher rate of malignancy was seen in all titers of the anti-TIF-1γ positive patients. In CADM, anti-TIF1-γ showed no correlation with clinical manifestations. The most common myositis associated autoantibody was anti-Ro-52 both in CADM and DM. In CADM, anti-Ro-52 was associated with Raynaud's phenomenon and chronic ILD, while in DM, anti-Ro-52 was associated with mechanic's hands, noninfectious fever and accompanied CTD.
CONCLUSION: Compared with DM, ILD is more likely to be acute in CADM. It is different between CADM and DM about the distribution of myositis autoantibodies and the clinical significance of the same myositis antibody, and the clinical significance of some myositis antibodies is related to titers.

Entities:  

Keywords:  Clinically amyopathic dermatomyositis; Dermatomyositis; Myositis autoantibody

Mesh:

Substances:

Year:  2020        PMID: 33331305      PMCID: PMC7745270     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  33 in total

1.  Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?

Authors:  Richard D Sontheimer
Journal:  J Am Acad Dermatol       Date:  2002-04       Impact factor: 11.527

Review 2.  Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis.

Authors:  Ernesto Trallero-Araguás; Jose Ángel Rodrigo-Pendás; Albert Selva-O'Callaghan; Xavier Martínez-Gómez; Xavier Bosch; Moisés Labrador-Horrillo; Josep Maria Grau-Junyent; Miquel Vilardell-Tarrés
Journal:  Arthritis Rheum       Date:  2012-02

Review 3.  Myositis-specific autoantibodies: detection and clinical associations.

Authors:  Sander H J van Dooren; Walther J van Venrooij; Ger J M Pruijn
Journal:  Auto Immun Highlights       Date:  2011-03-23

Review 4.  Recognition and Management of Myositis-Associated Rapidly Progressive Interstitial Lung Disease.

Authors:  Renea Jablonski; Sangeeta Bhorade; Mary E Strek; Jane Dematte
Journal:  Chest       Date:  2020-02-12       Impact factor: 9.410

5.  Myositis Autoantibodies: A Comparison of Results From the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot.

Authors:  Christopher A Mecoli; Jemima Albayda; Eleni Tiniakou; Julie J Paik; Umar Zahid; Sonye K Danoff; Livia Casciola-Rosen; Maria Casal-Dominguez; Katherine Pak; Iago Pinal-Fernandez; Andrew L Mammen; Lisa Christopher-Stine
Journal:  Arthritis Rheumatol       Date:  2020-01       Impact factor: 10.995

Review 6.  Clinically amyopathic dermatomyositis.

Authors:  Shinji Sato; Masataka Kuwana
Journal:  Curr Opin Rheumatol       Date:  2010-11       Impact factor: 5.006

7.  Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis.

Authors:  Hiroshi Mukae; Hiroshi Ishimoto; Noriho Sakamoto; Shintaro Hara; Tomoyuki Kakugawa; Seiko Nakayama; Yuji Ishimatsu; Atsushi Kawakami; Katsumi Eguchi; Shigeru Kohno
Journal:  Chest       Date:  2009-07-06       Impact factor: 9.410

8.  Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan.

Authors:  Yoshinao Muro; Kazumitsu Sugiura; Kei Hoshino; Masashi Akiyama; Koji Tamakoshi
Journal:  Arthritis Res Ther       Date:  2011-12-22       Impact factor: 5.156

9.  Value of Serum Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen in Evaluating Severity and Prognosis of Connective Tissue Disease-Associated Interstitial Lung Disease.

Authors:  Qian Jin; Jisheng Zheng; Xianrong Xu; Yeming Hu; Ying Zhou; Weihua Xu; Feihua Huang
Journal:  Arch Rheumatol       Date:  2017-10-16       Impact factor: 1.472

10.  2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.

Authors:  Ingrid E Lundberg; Anna Tjärnlund; Matteo Bottai; Victoria P Werth; Clarissa Pilkington; Marianne de Visser; Lars Alfredsson; Anthony A Amato; Richard J Barohn; Matthew H Liang; Jasvinder A Singh; Rohit Aggarwal; Snjolaug Arnardottir; Hector Chinoy; Robert G Cooper; Katalin Dankó; Mazen M Dimachkie; Brian M Feldman; Ignacio Garcia-De La Torre; Patrick Gordon; Taichi Hayashi; James D Katz; Hitoshi Kohsaka; Peter A Lachenbruch; Bianca A Lang; Yuhui Li; Chester V Oddis; Marzena Olesinska; Ann M Reed; Lidia Rutkowska-Sak; Helga Sanner; Albert Selva-O'Callaghan; Yeong-Wook Song; Jiri Vencovsky; Steven R Ytterberg; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheumatol       Date:  2017-10-27       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.